Breaking News, Collaborations & Alliances

Sanofi, Teva Partner on Inflammatory Bowel Disease Treatment

Collaboration leverages the innovative R&D and commercial expertise of both companies.

Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., will co-develop and co-commercialize asset TEV’574, currently in Phase 2b trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

Under the new collaboration agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement. Sanofi will lead the development of the Phase 3 program.

Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

Paul Hudson, CEO Sanofi said, “Anti-TL1As are a promising class of therapies, and we believe that TEV’574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.”

Richard Francis, President, and CEO Teva said, “This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy. This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters